GLP-1 receptor agonist research matures
Early GLP-1 receptor agonists established the principle that incretin pathway activation can influence glucose homeostasis and appetite regulation. These single-receptor compounds provided the foundation for multi-receptor approaches.
Dual agonist concept emerges
Researchers began exploring whether activating two incretin receptors simultaneously (GIP and GLP-1) could produce effects beyond what single-receptor agonism achieved. Early dual agonist peptides demonstrated that multi-receptor activation was feasible and could produce additive or synergistic metabolic effects.
Glucagon receptor added to the research framework
Studies explored the counterintuitive idea that glucagon receptor activation — traditionally associated with glucose elevation — could contribute to metabolic benefits when combined with incretin receptor agonism. Researchers documented glucagon's effects on energy expenditure, lipid metabolism, and hepatic fat reduction.
Retatrutide designed as triple agonist
Eli Lilly researchers designed retatrutide (LY3437943) as a 39-amino acid peptide linked to a C20 fatty diacid moiety, engineered to activate GIP, GLP-1, and glucagon receptors simultaneously. The fatty acid modification extended the compound's half-life for once-weekly research dosing.
Phase 1 data published
Initial clinical pharmacology data established the safety and pharmacokinetic profile of retatrutide in human subjects. Dose-escalation studies documented tolerability across a range of doses and provided the basis for Phase 2 trial design.
Phase 2 trial published in NEJM
Jastreboff et al. published results of a 48-week Phase 2 trial in the New England Journal of Medicine examining retatrutide in adults with obesity. Researchers observed dose-dependent changes in body weight and metabolic parameters across treatment groups.
N Engl J Med · PMID: 37366315
Hepatic fat and meta-analysis research
A study in Nature Medicine examined retatrutide's effects on hepatic fat content in subjects with metabolic dysfunction-associated steatotic liver disease. Separately, a meta-analysis of three RCTs encompassing 878 patients documented statistically significant effects on body weight, BMI, waist circumference, fasting glucose, and HbA1c.
Nat Med
Phase 3 TRIUMPH trial results
Phase 3 TRIUMPH-4 trial results demonstrated significant improvements in both weight and pain scores in subjects with knee osteoarthritis over 68 weeks. Multiple additional Phase 3 trials continue to evaluate retatrutide across different metabolic research endpoints.
Why This Research Matters
The progression from single to dual to triple receptor agonism represents a clear evolution in metabolic peptide research strategy. Each step added complexity but also expanded the range of metabolic pathways being engaged simultaneously. Retatrutide's research trajectory — from concept to Phase 3 trials in less than a decade — reflects both the maturity of incretin biology and the growing sophistication of multi-target peptide design. The inclusion of glucagon receptor agonism was particularly noteworthy, as it challenged assumptions about glucagon's role in metabolic regulation.
Explore More
Compound Research Kits
All information presented in this article references published research literature and is intended for educational purposes only. Research peptides are sold strictly for laboratory research use and are not approved for human consumption or medical treatment.